VERTEX PHARMACEUTICALS INC / MA Interest Expense on Debt
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Interest Expense on Debt of $0 for the 12-month period ending 2012-12-31, per its 10-K filed 2013-03-01.
Discontinued › Expense Statement › Interest Expense
us-gaap:InterestExpenseDebt · last filed 2013-03-01
- VERTEX PHARMACEUTICALS INC / MA interest expense, debt for the quarter ending 2012-03-31 was $0.00, a 100.00% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA interest expense, debt for the quarter ending 2011-12-31 was $7.93M, a 100.46% increase year-over-year.
- VERTEX PHARMACEUTICALS INC / MA interest expense, debt for the quarter ending 2011-09-30 was $2.96M, a 22.65% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA interest expense, debt for the quarter ending 2011-06-30 was $2.86M, a 22.66% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA interest expense, debt for fiscal 2012 was $0.00, a 100.00% decline from fiscal 2011.
- VERTEX PHARMACEUTICALS INC / MA interest expense, debt for fiscal 2011 was $21.69M, a 43.93% increase from fiscal 2010.
- VERTEX PHARMACEUTICALS INC / MA interest expense, debt for fiscal 2010 was $15.07M, a 334.86% increase from fiscal 2009.
- VERTEX PHARMACEUTICALS INC / MA interest expense, debt for fiscal 2009 was $3.46M.
| Period end | Interest Expense, Debt 3 month | Interest Expense, Debt 6 month | Interest Expense, Debt 9 month | Interest Expense, Debt 12 month |
|---|---|---|---|---|
| 2012-12-31 | $0.00 10-K · filed 2013-03-01 | |||
| 2012-03-31 | $0.00 10-Q · filed 2012-05-10 | $7.93M derived: sum of 2 quarters · filed 2013-03-01 | $10.89M derived: sum of 3 quarters · filed 2013-03-01 | $13.75M derived: sum of 4 quarters · filed 2013-03-01 |
| 2011-12-31 | $7.93M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-01 | $10.89M derived: sum of 2 quarters · filed 2013-03-01 | $13.75M derived: sum of 3 quarters · filed 2013-03-01 | $21.69M 10-K · filed 2013-03-01 |
| 2011-09-30 | $2.96M 10-Q · filed 2012-11-06 | $5.82M derived: sum of 2 quarters · filed 2012-11-06 | $13.76M 10-Q · filed 2012-11-06 | $17.71M derived: sum of 4 quarters · filed 2013-03-01 |
| 2011-06-30 | $2.86M 10-Q · filed 2012-08-08 | $10.80M 10-Q · filed 2012-08-08 | $14.75M derived: sum of 3 quarters · filed 2013-03-01 | $18.58M derived: sum of 4 quarters · filed 2013-03-01 |
| 2011-03-31 | $7.93M 10-Q · filed 2012-05-10 | $11.89M derived: sum of 2 quarters · filed 2013-03-01 | $15.72M derived: sum of 3 quarters · filed 2013-03-01 | $19.42M derived: sum of 4 quarters · filed 2013-03-01 |
| 2010-12-31 | $3.96M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-01 | $7.78M derived: sum of 2 quarters · filed 2013-03-01 | $11.48M derived: sum of 3 quarters · filed 2013-03-01 | $15.07M 10-K · filed 2013-03-01 |
| 2010-09-30 | $3.83M 10-Q · filed 2011-11-03 | $7.53M derived: sum of 2 quarters · filed 2011-11-03 | $11.11M 10-Q · filed 2011-11-03 | |
| 2010-06-30 | $3.70M 10-Q · filed 2011-08-09 | $7.29M 10-Q · filed 2011-08-09 | ||
| 2010-03-31 | $3.58M 10-Q · filed 2011-05-06 | |||
| 2009-12-31 | $3.46M 10-K · filed 2012-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |